Immune-mediated thrombocytopenic purpura: Difference between revisions
From IDWiki
(Imported from text file) Â |
(→â€) |
||
Line 1: | Line 1: | ||
== |
==Definition== |
||
* |
*Acquired autoimmune bleeding disorder characterized by autoimmune autobody-mediated destruction of platelets |
||
== |
==Differential Diagnosis== |
||
* |
*Primary |
||
* |
*Secondary |
||
** |
**Infection |
||
*** |
***[[HIV]] |
||
*** |
***[[Hepatitis C virus]] |
||
*** |
***[[CMV]] |
||
*** |
***[[VZV]] |
||
*** |
***[[Helicobacter pylori]] |
||
** |
**Inflammatory/Autoimmune |
||
*** |
***[[Antiphospholipid antibody syndrome]] |
||
*** |
***[[Autoimmune thrombocytopenia]] (Evans syndrome) |
||
** |
**Congenital: [[common variable immune deficiency]] |
||
**Neoplasm: [[lymphoproliferative disorder]] |
|||
*** Common variable immune deficiency |
|||
⚫ | |||
** Neoplasm |
|||
*** Lymphoproliferative disorders |
|||
⚫ | |||
== |
==Investigations== |
||
* |
*CBC |
||
** |
**Mean platelet volume can suggest high platelet turnover |
||
* |
*Peripheral blood film |
||
* |
*HIV and HCV testing |
||
* |
*Additional |
||
** |
**Abdo ultrasound for splenomegaly and liver disease |
||
** |
**Rh status |
||
** |
**DAT for Evan's syndrome |
||
** |
**Quantitative immunoglobulins |
||
** |
**Hep B testing |
||
** |
**H. pylori, if at risk |
||
** |
**Antiphospholipid antibodies |
||
** |
**ANA, anti-dsDNA |
||
** |
**Thyroid tests |
||
** |
**vWF testing (for type 2B vWD) |
||
** |
**Bone marrow biopsy |
||
== |
==Management== |
||
=== Acute management === |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
[[Category:Hematology]] |
[[Category:Hematology]] |
Revision as of 15:12, 29 July 2020
Definition
- Acquired autoimmune bleeding disorder characterized by autoimmune autobody-mediated destruction of platelets
Differential Diagnosis
- Primary
- Secondary
- Infection
- Inflammatory/Autoimmune
- Antiphospholipid antibody syndrome
- Autoimmune thrombocytopenia (Evans syndrome)
- Congenital: common variable immune deficiency
- Neoplasm: lymphoproliferative disorder
- Medications
Investigations
- CBC
- Mean platelet volume can suggest high platelet turnover
- Peripheral blood film
- HIV and HCV testing
- Additional
- Abdo ultrasound for splenomegaly and liver disease
- Rh status
- DAT for Evan's syndrome
- Quantitative immunoglobulins
- Hep B testing
- H. pylori, if at risk
- Antiphospholipid antibodies
- ANA, anti-dsDNA
- Thyroid tests
- vWF testing (for type 2B vWD)
- Bone marrow biopsy
Management
Acute management
- Only needs treatment if platelets lower than 30 or if bleeding
- First-line:
- Steroids
- Prednisone 1-2mg/kg/day x3weeks then taper (70-80% response but high relapses over next 10 years)
- Dexamethasone 40mg/d po x4days ever 2-4 weeks, repeated for 3-6 cycles (90% response)
- IVIg 1-2g/kg x1-2 days, if refractory to steroids or requires rapid treatment
- Anti-D if Rh positive and has a spleen
- Steroids
- Second-line:
- Splenectomy
- Ensure vaccinated for Hib, Strep pneumo, and N. meningitidis
- Rituximab
- Thrombopoeitin agonists: eltrombopag or romiplostim
- Immunosuppressive therapies: azathioprine, cyclosporin A, cyclophosphomide, danazol, dapsone, mycofenolate mofetil, vina alkaloids
- Splenectomy
- Third-line:
- Almtuzumab, chemotherapy, stem cell transplant
- For life-threatening bleed:
- IVIG 1g/kg, repeated once more if platelets remain below 50 the next day
- Pulse steroids: methylprednisolone 30mg/kg IV daily x2-3 days)
- Tranexamic acid 1G IV q6h
- Platelet transfusion
- Emergency splenectomy
- Last-ditch: recombinant factor VIIa 90mcg/kg IV q2h
- High risk for clotting